LOGO Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement ("Agreement") is made between Tango Therapeutics, Inc., a Delaware corporation (the "Company"), and Malte Peters, M.D. (the "Executive"), and is effective as of the Effective Date, as defined in Section 23 herein. WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the new terms and conditions contained herein. NOW, THEREFORE, in consideration of the mutual covenants and agreements he ...

LOGO Exhibit 99.1 During the presentation, Atea will provide an update on the progress of its global Phase 3 program evaluating the potential best-in-class regimen of bemnifosbuvir (BEM) and ruzasvir (RZR) for the treatment of Hepatitis C virus (HCV). The Company will also detail challenges with current HCV therapeutics and the potential of Atea's regimen to meaningfully address them. In addition, the Company will discuss opportunities to expand HCV treatment through further adoption of the test-and-treat m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 ASTRONICS CORPORATION (Exact name of registrant as specified in its charter) New York 0-7087 16-0959303 (State of Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 130 Commerce Way East Aurora, New York 14052 (Address of principal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 CURRENT REPORT GOLUB CAPITAL BDC, INC. Delaware 814-00794 27-2326940 (State or Other Jurisdiction of Incorporation) Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2026 FORM 8-K (Exact name of Registrant as Specified in Its Charter) (Commission File Number) (IRS Employer Identification No.) __ 200 Park Avenue, 25th Floor, New York, NY 10166_ _ (Address of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2026 Xilio Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40925 85-1623397 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 (Address ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 Image_0.jp ARDELYX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (Commission File Number) Delaware 001-36485 26-1303944 (IRS Employer Identification Number) 400 FIFTH AVE., SUITE 210, WALTHAM, MASSACHUSETTS 02451 (Add ...

slide l fi w w w.n e w t e k o n e.c o m N A S D A Q: N E W T I n v e s t o r D a y 2 0 2 6 J a n u a ry 8 , 2 0 2 6 H o s t e d a n d P r e s e n t e d b y: B a rry S l o a n e , C h a i r m a n , P r e s i d e n t & C E O F r a n k M. D e M a r i a , E V P & C h i e f F i n a n c i a l O ffi c e r P e t e r D o w n s , P r e s i d e n t , N e w t e k B a n k , N.A. A n d r e w K ap l a n , C h i e f S t r a t e g y O ffi c e r I n v e s t o r R e l a t i o n s B ry c e R o w e b r o w e @ n e w t e k o n ...

Exhibit No. 99.1 News Release https://files.reportify.c As of November 30, 2025, cash, cash equivalents and restricted cash totaled $3.0 billion and available liquidity was nearly $1.9 billion. During the quarter, CMC repurchased 663,220 shares of common stock valued at $38.9 million in the aggregate. As of November 30, 2025, $166.1 million remained available under the current share repurchase authorization. The cash balance at November 30, 2025 included $2.0 billion in proceeds from an offering of senior n ...

财务数据关键指标变化：收入和利润 - 截至2025年11月29日的十三周净销售额为3.402亿美元，同比下降0.3%[92][96] - 截至2025年11月29日的十三周毛利润为1.099亿美元，同比下降15.8%[98] - 截至2025年11月29日的十三周营业利润为3758.4万美元，占净销售额的11.0%[96] - 截至2025年11月29日的十三周净利润为2526.9万美元，同比下降1285.3万美元[96][104] - 公司净收入为2526.9万美元，相比去年同期的3812.2万美元下降33.7%[108] - 调整后EBITDA为5562.4万美元，占净销售额的16.4%[96] - 调整后EBITDA为5562.4万美元，同比下降1444.4万美元或20.6%，主要受毛利下降驱动[105][108] 财务数据关键指标变化：成本和费用 - 截至2025年11月29日的十三周毛利率为32.3%，同比下降590个基点[93][96][98] - 销售成本为2.30298亿美元，同比增长9.3%[96][97] - 销售与营销费用为2967.7万美元，同比下降10.1%[96][99] - 一般及行政费用为3800.6万美元，同比下降0.2%[96][99] - 利息支出为428.6万美元，同比减少357.5万美元或45.5%[108] - 折旧及摊销费用为620.5万美元，同比增加115.8万美元或22.9%[108] 现金流表现 - 经营活动产生的现金流量净额为5009.4万美元，同比增加1810万美元或56.5%[129] - 投资活动净现金使用额为210万美元，较上年同期70万美元增长200%[130] - 2025财年十三周投资活动现金主要用于购买物业和设备，金额为210万美元[130] - 2024财年同期投资活动现金使用包括30万美元购买物业和设备及40万美元投资无形资产和其他资产[130] - 融资活动净现金提供额为4760万美元，上年同期为净现金使用4230万美元[131] - 2025财年十三周融资活动现金主要来自发行长期债务所得1.5亿美元及期权行权所得110万美元[131] - 2025财年十三周融资活动现金使用包括9960万美元回购普通股及120万美元支付股权激励相关税费[131] - 2024财年同期融资活动现金使用包括5000万美元偿还定期贷款本金及230万美元支付股权激励相关税费[131] - 2024财年同期融资活动现金部分被期权行权所得1000万美元抵消[131] 资本结构与融资活动 - 截至2025年11月29日，公司定期贷款未偿还余额增至4亿美元[102] - 期末定期贷款（Term Facility）未偿还本金余额为4亿美元，到期日为2030年3月[124] - 公司遵守了所有债务契约，总净杠杆率未超过6.00:1.00的限制[123] 股东回报与资本配置 - 公司在截至2025年11月29日的十三周内，以平均每股19.99美元的价格回购了4,983,514股普通股，总金额约9960万美元[125] - 股票回购计划总额增至3亿美元，截至2025年11月29日仍有约7100万美元的授权回购额度[125][126] 其他财务数据 - 截至2025年11月29日，公司现金及现金等价物为1.941亿美元[110] 其他重要内容 - 公司在截至2025年11月29日的十三周内市场风险敞口无重大变化[134]

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2026 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Identification No.) 7 Times Square, Suite 2503 New York, ...